Pfizer Inc
NYSE: PFE
$26.17
+$0.52 (+2.0%)
Closing Price on November 25, 2024
PFE Articles
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Published:
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Beyond Meat, Biogen, Eli Lilly, Levi Strauss, Nvidia, Pfizer, Plug Power, Raytheon, Square and Wayfair.
Published:
Last Updated:
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
Published:
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Published:
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Caterpillar, Corning, DexCom, Enphase Energy, First Solar, Invesco, 3M, Microsoft, Pfizer and Wynn Resorts.
Published:
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Published:
This week will be perhaps the biggest week of earnings season, with many major names reporting, including Amazon, Facebook, Ford and Starbucks.
Published:
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Published:
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published: